News Toleranzia AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 16:07:47 15/05/2024 BST			5-day change	1st Jan Change
0.566 ^SEK	+7.20%		+13.20%	+32.24%

02-23	Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
02-23	Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Toleranzia AB: Annual report for the financial year 2023	04-30	AQ
Toleranzia AB receives loan commitment of SEK 20 million	04-24	AQ
Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program	03-18	AQ
Toleranzia AB – Year-End Report 2023	02-23	AQ
Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-23	CI
Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Toleranzia successfully completes GLP toxicology study of TOL2	01-15	AQ
Toleranzia AB Successfully Completes GLP Toxicology Study of TOL2	01-15	CI
Toleranzia AB starts production of finished drug product for clinical studies	12-21	AQ
Toleranzia AB Starts Production of Completed Drug Product for Clinical Studies	12-21	CI
Toleranzia AB presents Nomination Committee	12-15	AQ
Toleranzia AB Announces Nomination Committee	12-15	CI
Toleranzia reports positive feedback from meeting with the Danish Medicines Agency	12-06	AQ
Toleranzia AB: Interim report third quarter 2023	27/10/23	AQ
Toleranzia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/10/23	CI
Toleranzia Appoints Successor to Outgoing CFO	16/10/23	MT
Toleranzia appoints Thomas Pålsson as new Chief Financial Officer	16/10/23	AQ
Toleranzia AB Announces Executive Changes	16/10/23	CI
Toleranzia starts toxicology study of its lead drug candidate TOL2	26/09/23	AQ
Toleranzia AB Starts Toxicology Study of its Lead Drug Candidate TOL2	26/09/23	CI

No results for this search